SLXN · Silexion Therapeutics Corp · Investor Relations

Substantial doubt about the company's ability to continue as a going concern.

“our management has concluded that we do not have sufficient cash to fund our operations for 12 months from the issuance date of our consolidated financial statements for the three-month and six-month periods ended June 30, 2026 included in this quarterly report, but rather, under our current business plan, through the fourth quarter of 2026 and, as a result, there is substantial doubt about our ability to continue as a going concern.”